Almac Discovery received approval to initiate its Phase I dose escalation study to investigate subcutaneous ALM201 in advanced ovarian cancer and other solid tumors. The company began dosing the first patient with ALM201, a therapeutic peptide derived from FKBPL, a natural protein that binds CD44. ALM201 has multiple modes of action including anti-angiogenesis, a mechanism that is particularly relevant in ovarian cancer.
 
Epithelial ovarian cancer (EOC) is among the top ten diagnosed cancers, with the most common type being high-grade serous ovarian cancer (HGSOC), which represents an area of unmet medical need. 
 
Stephen Barr, president of Almac Discovery said, “I am particularly pleased by the progress of our novel drug candidate ALM201 into clinical development. The drug is the culmination of significant effort by the Almac team over the past years and we believe that it will prove to be an essential complement to the oncologist’s armamentarium.”